Published on

FDA Approves 30-Minute Onset Label for ADHD Med

Stimulant medication may be useful for controlling children's symptoms in the mornings

The FDA has approved a new labeling, 30-minute onset of action, for Focalin XR (dexmethylphenidate HCl) extended-release capsules for the treatment of attention deficit hyperactivity disorder (ADHD), bringing potential benefits for children and their families during the morning period when they are preparing for school.

The new labeling is based on clinical data from a study from Baylor College of Medicine. In the study of 86 children with ADHD between the ages of six and 12, Focalin XR (from Novartis Phamaceuticals) provided significant improvements at 30 minutes post-dose compared to placebo in measures of attention, deportment, and academic productivity.

The extended-release medication also helps patients manage symptoms for up to 12 hours. The most common side events were dyspepsia, decreased appetite, headache and anxiety in pediatric studies; and dry mouth, dyspepsia, feeling jittery, dizziness, headache and anxiety in adult studies.

Read more about the medication.

Copyright © 1998 - 2013 New Hope Media LLC. All rights reserved. Your use of this site is governed by our
Terms of Service ( and
Privacy Policy (
ADDitude does not provide medical advice, diagnosis, or treatment. The material on this web site is provided for educational purposes only.
See additional information at
New Hope Media, 39 W. 37th Street, 15th Floor, New York, NY 10018

Adult ADHD | Parenting ADHD Children | ADHD Treatment | School & Learning Disabilities | About ADHD | ADHD Resources | ADHD Community
Source: FDA Approves 30-Minute Onset Label for ADHD Med